Abbreviations: AASLD, the American Association for the Study of the Liver; ALT, alanine aminotransfease; anti-HBc, antibody to hepatitis B core antigen; anti-HBs, antibody to hepatitis B surface antigen; APASL, Asia-Pacific Association for the Study of the Liver; C/EBPα, CCAAT/enhancer-binding protein α; cccDNA, covalently closed circular DNA; CHB, chronic HBV infection; CI, confidence interval; CMA, Chinese society of hepatology; CNKI, China National Knowledge Infrastructure; EASL, European Association for the Study of the Liver; HAV, hepatitis A virus; HBeAg, hepatitis Be antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HDV, hepatitis D virus; KASL, the Korean Association for the Study of the Liver; mTOR, mammalian target of rapamycin; NAs, nucleos(t)ide analogues; OR, odds ratio; YMDD, tyrosine-methionine-aspartate-aspartate. † These authors contributed equally to this study and share corresponding authorship. 
Summary

| INTRODUCTION
HBV infection is a global public issue, and it is estimated that approximately 400 million patients have chronic HBV infection worldwide. 1 China is one of the major endemic countries of HBV in the world. The prevalence of chronic HBV infection in the Chinese population aged 1-59 is as high as 7.2% when compared with 0.3%-0.5% carrier rate in Western countries. 2, 3 HBV reactivation is documented in patients with breast cancer receiving anticancer chemotherapy. [4] [5] [6] As adjuvant chemotherapy is a basic part for breast cancer treatment, HBV reactivation has become a significant clinical problem for those breast cancer patients with chronic HBV infection, especially in China which experiences increasing breast cancer incidence, with a twofold greater increase than the world average in recent years. 7 HBV reactivation results in interruption of the chemotherapy schedule which makes prognosis for cancer management uncertain. The degree of liver dysfunction attributed to HBV reactivation can be asymptomatic, moderate, fulminant or even lead to hepatic failure or mortality potentially. 8 Several studies have
shown NAs prophylaxis can decrease hepatitis B flare and the severity of hepatitis attributed to HBV reactivation. 5, [9] [10] [11] In breast oncology, risk factors for hepatitis B flare can be HBV serologic status and chemotherapy regimen which have a great influence on reactivation rates which vary from 41%-56%. 4, 5 Thus, identifying risk factors can inform different prognosis for HBV carriers and guide clinical strategies. However, there are very few review articles illustrating the risk for breast cancer. We comprehensively conclude that not only viral status and traditional chemotherapy regimen are important, but also emerging targeting drugs such as "everolimus" may be associated with HBV reactivation, which are newly applied in breast cancer chemotherapy.
In this study, we reviewed the basis for managing HBV reactivation including the following: risk factors, screening and prophylactic antiviral therapy. Moreover, we conducted an up-to-date meta-analysis to assess lamivudine prophylaxis efficacy as well as lamivudine prophylaxis-related drug resistance in HBsAg-positive breast cancer patients undergoing chemotherapy and propose a practical strategy for management of HBV reactivation.
| Overview of HBV reactivation
The natural course of HBV reactivation depends on the interplay between virus replication and host immune control. 16, 17 In these patients, the immunosuppression chemotherapy disables host immunity which keeps under control "dormant" HBV and results in HBV reactivation. HBV reactivation in patients with breast cancer occurs after the first 1-6 cycles of chemotherapy (median 3 cycles) and peak alanine aminotransferase (ALT) level are recorded following the peak HBV DNA with a time lag of 2-3 weeks. 4, 18 Some patients with cancer experience asymptomatic HBV reactivation accompanied by serum ALT increases during chemotherapy; others may develop severe fulminant hepatitis and hepatic failure which can lead to the death of patients with cancer. 
K E Y W O R D S
breast cancer, hepatitis B, lamivudine, prophylaxis antiviral therapy, reactivation strategies via assessing these factors. These risk factors are summarized and expanded below. . [29] [30] [31] Research shows that intrahepatic covalently closed circular DNA (cccDNA) which is the template for the replicative intermediate, namely pregenomic RNA, highly correlates with HBV reactivation with a specificity of 100% and an accuracy of 88.9%. [32] [33] [34] As cccDNA is detectable in the hepatocyte nucleus, intrahepatic cccDNA level can be used as a risk factor for HBV reactivation in patients with cleared HBV infection. In addition, serum cccDNA\serum HBV DNA ratio can be used as a severity index of HBV reactivation, but further studies are required to elucidate this ratio further. 
| Virus status
| Molecular targeted drug everolimus
Everolimus is the mammalian target of rapamycin (mTOR) 48, 49 However, the hepatitis B exacerbation may be attributable to the strong immunosuppressive effects of everolimus, as it is commonly used as an immunity inhibitor after organ transplantation. 50, 51 Interestingly, the HBV serologic status of the two foregoing cases was characterized by IgM anti-HBc negativity, which indicates they potentially had cleared/occult HBV infection. 52, 53 On the background of cleared/occult HBV infection, the overt HBV reactivation rates that occur are lower than in HBsAg-positive patients, reaching 1% in some clinical trials. 54 Yet, these patients tend to develop de novo HBVrelated hepatitis which results in higher fulminant hepatic failure rates and mortality. In some case series, nearly 20%-37.5% of patients had fatal fulminant hepatitis. 55, 56 This scenario of low HBV reactivation rates but high fatal fulminant hepatitis risk raises concern and more systematic data are needed to illustrate the mechanism of the severity of de novo HBV-related hepatitis.
| Prevention and prophylaxis management 1.3.1 | Screening
Intervention is consequentially inferior to prevention before reactivation. Thus, the key in prevention is the screening of patients at risk of reactivation by establishing their viral status and taking their chemotherapy regimen into consideration. As a vast proportion of patients with cancer are not aware of their chronic HBV infection and they might not recognize that they are at high risk of fulminant hepatitis, it is of great importance to screen for HBV serological markers given the potential poor outcome of reactivation. Although targeted screening can be cost-effective, it is not advocated. 
| Prophylactic use of antiviral drugs
Although antiviral drugs, NAs, can suppress HBV reactivation, liver function may be significantly compromised as a result of previous high viral replication. Such situations may have potentially missed the optimal time point for antiviral therapy. Therefore, especially for breast cancer specialists, defining optimal time for intervention is essential.
According to recent studies, the intervention strategies can be divided investigators decide lamivudine use, we suggest that deferred preemptive therapy is an alternative therapeutic intervention. In fact, two randomized controlled studies have proven that prophylactic therapy is far more effective than pre-emptive therapy in patients with lymphoma and the reactivation rate in the pre-emptive therapy group was close to the rates in the therapeutic group.
63,67
Prophylaxis management is not requisite for all patients with breast cancer undergoing chemotherapy. Several guidelines recommend that HBsAg-positive or HBV DNA-positive cancer patients should be tested for baseline HBV DNA levels and use NAs before the initiation of chemotherapy regardless of HBV DNA levels. [58] [59] [60] [61] As for cleared/occult HBV infection patients, they have lower risks for reactivation than HBsAg-positive patients when exposed to chemotherapy. The recommendation is to monitor ALT, HBV DNA and HBsAg and be treated with NAs upon confirmation of HBV reactivation. [57] [58] [59] Considering high risks for cleared/occult HBV-infected patients such as everolimus, intense anthracycline and steroids, we suggest that these patients with breast cancer should receive prophylactic antiviral therapy before the initiation of chemotherapy. 68 In addition, prophylactic therapy is expensive and it will, however, lead to the possibility of overtreatment for nearly half of the patients with cancer without HBV reactivation. We propose that clinicians can use risk calculations to decide whether patients with breast cancer require prophylactic Knowledge Infrastructure (CNKI) by use of the keywords "chemotherapy," "breast," "cancer," "carcinoma," "HBV," "reactivation," "prophylaxis," "preemptive," and "lamivudine". The search was performed in
June 2016 without limitation of language and time. This study was restricted to human studies and includes all clinical trials regardless of randomized, controlled, prospective and retrospective design. This study excluded the following: (i) meeting abstracts, reviews and case reports; (ii) studies that did not contain prophylaxis and nonprophylaxis groups; (iii) studies that involved HCV, HDV and human immunodeficiency virus co-infection; and (iv) studies that included patients receiving no immunosuppressive chemotherapy.
| Definition
The criteria of HBV reactivation were (i) HBV DNA level rise (≥10-fold increase greater than baseline level or the absolute value of HBV DNA copy exceeded 1×10 9 copies/mL); (ii) HBV DNA from undetectable 
| Statistical analysis
We performed meta-analysis by using Review Manager Software version 5.0 for windows (Cochrane Collaboration, Oxford, UK). Statistical heterogeneity was assessed by the chi-squared and I-squared test. In these tests, P<.10 was regarded as significant heterogeneity. The outcome was measured as odds ratio (OR) with 95% confidence intervals (CI). A random effect model was applied for analysis in the cases where significant heterogeneity existed. A fixed effect model was applied in other cases. P<.05 was used to indicate statistical significance.
| RESULT
| Search results and description of studies
In all, 142 papers were obtained and screened for retrieval via using the searching strategy mentioned above. After screening for title and abstract, 125 studies were excluded and 17 were retrieved for further assessment. Ultimately, nine studies were removed by the exclusion criteria and eight studies were included by using strict inclusion criteria. 5, 66, [74] [75] [76] [77] [78] [79] Details on study selection are listed in Fig. S1 .
One study was a randomized controlled study, 74 two were retrospective cohort studies, 75, 76 and five were prospective cohort studies. 5, 66, 76, 77, 79 Seven studies compared prophylactic lamivudine administration with nonprophylaxis management 5, [74] [75] [76] [77] [78] [79] and one evaluated the efficacy-effectiveness distinction between prophylactic lamivudine management and deferred pre-emptive lamivudine management. 66 We combined therapeutic strategy with deferred pre-emptive strategy into one concept as we have discussed deferred pre-emptive strategy is another kind of therapeutic strategy above.
The populations of the eight studies were HBsAg positive and were all Asian, with five from China and three from Korea.
| Comparing occurrence rates of hepatitis attributed to HBV reactivation between the prophylaxis and nonprophylaxis groups
The six studies which included 232 patients in the prophylaxis group and 387 patients in the nonprophylaxis group reported hepatitis events attributable to HBV reactivation. Meta-analysis revealed that there is a significant difference in hepatitis attributed to HBV reactivation between the lamivudine prophylaxis and nonprophylaxis group (OR=0.15, 95%
CI: 0.07-0.35, P<.00001) (Figure 2 ). There was no significant heterogeneity among the six studies (chi-squared=2.47, I
2 =0%, P=.65).
| Comparing chemotherapy disruption rates attributed to HBV reactivation between the prophylaxis and nonprophylaxis groups
The six studies which included 228 patients in the prophylaxis group 
| Comparing YMDD mutation rates related to lamivudine prophylaxis between the prophylaxis and nonprophylaxis groups
Only four patients had YMDD mutations in the six studies which included 226 patients in the prophylaxis group and 346 patients in the nonprophylaxis group. Patients with lamivudine prophylaxis had higher risk for YMDD mutations statistically (OR=6.33, 95% CI: In the past, we have focused on patients with lymphoma or undergoing hematopoietic stem cell transplantation and efficacy of prophylactic lamivudine use in these patients. 80, 81 Little attention prophylactic antiviral management of patients with breast cancer has been paid. In this meta-analysis, we have discussed the necessity of antiviral therapy prophylaxis for HBsAg-positive breast cancer patients. However, there are several obstacles to be addressed.
According to another meta-analysis, approximately 85% of patients with breast cancer are overtreated with lamivudine for only 15% patients had developed HBV reactivation in the nonprophylaxis group.
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Therefore, most HBsAg-positive breast cancer patients will benefit from a reactivation risk predictive model. Further work is required to illustrate the risk predictive model in breast cancer.
In addition, we noticed that patients with lamivudine prophylaxis had a higher risk of YMDD mutations statistically in our study, while there was no significant difference in YMDD mutation rate between the prophylaxis and nonprophylaxis groups (95% CI: 0.60-48.95 and P=.13 in another meta-analysis). 64 It should be noted that three of the four patients had received long-term lamivudine treatment with a duration time over 18 months. 75, 76 Prolonged lamivudine use can result in increasing likelihood of YMDD mutants. Studies have reported that YMDD mutations emerged in 24% of chronic HBV-infected patients in the first year of lamivudine treatment, 38% in the second year, 50% in the third year and 67% in the fourth year. 70, 82, 83 We suggest that lamivudine should no longer be regarded as first-line drug for prophylactic management, even though we have some available remedial measures when HBV YMDD mutants arise. Those NAs such as entecavir and tenofovir which have higher barriers to resistance have proved to be more efficient in preventing HBV reactivation, reducing HBV-related mortality and lowering chemotherapy disruption rates. 84, 85 No matter what, prophylactic antiviral therapy plays a prerequisite "escort" role during chemotherapy for those breast cancer patients with CHB (as shown in Figure 5 ).
Undoubtedly, our study has several limitations to be considered.
First, we conducted this meta-analysis based on eight studies but not on patients' data. Confounding variables such as different chemotherapy schemes, cancer metastasis and patients comorbidities were not taken into account. Second, some studies included had small sample sizes. We need more data to evaluate the relationship between lamivudine prophylaxis and YMDD mutation rate because of the P=.05 value.
In conclusion, our study showed that lamivudine prophylaxis is ef- 
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F I G U R E 5 A cartoon depicting the dynamic situation of HBV virus replication and host immune control during chemotherapy with antiviral therapy
